Literature DB >> 8943863

Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta T-cell origin.

C B Cooke1, L Krenacs, M Stetler-Stevenson, T C Greiner, M Raffeld, D W Kingma, L Abruzzo, C Frantz, M Kaviani, E S Jaffe.   

Abstract

We identified eight cases of T-cell lymphoma with evidence of a gamma delta phenotype over a 13-year period. Seven of these cases conformed to a distinct clinicopathologic entity of hepatosplenic gamma delta T-cell lymphoma. Nearly all of these patients were young adult males (five of seven), with a median age at presentation of 20 years. They presented with marked hepatosplenomegaly, without lymphadenopathy or significant peripheral blood lymphocytosis. Thrombocytopenia was seen in all patients, and five of seven were mildly anemic. The clinical course was aggressive, and despite multiagent chemotherapy, the median survival duration was less than 1 year. The morphologic findings were uniform; a monomorphic population of medium-sized lymphoid cells with moderately clumped chromatin and a rim of pale cytoplasm infiltrated the sinusoids of the spleen, liver, and bone marrow. The cells had a characteristic immunophenotype: CD2+, CD3+, CD4-, CD5-, CD7+, CD16+, CD57-, CD25-, T-cell receptor (TCR)delta +, beta F1-. CD8 was positive in four of seven cases tested, and CD56 was positive in five of six. All cases expressed the cytotoxic granule-associated protein, TIA1, but perforin was detected in only one case. All cases with assessable DNA had a TCR gamma gene rearrangement, and lacked Epstein-Barr virus sequences. Isochromosome 7q was identified in two cases with cytogenetic information. The one case of cutaneous gamma delta T-cell lymphoma differed in its clinical manifestations, histologic appearance, and immunophenotype. We conclude that hepatosplenic gamma delta T-cell lymphoma is a distinct clinicopathologic entity derived from cytotoxic gamma delta T cells, and should be distinguished from other lymphomas of T-cell and natural-killer cell (NK)-like T-cell derivation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943863

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

1.  Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior.

Authors:  E Berti; D Tomasini; M H Vermeer; C J Meijer; E Alessi; R Willemze
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

2.  Hepatosplenic and subcutaneous panniculitis-like gamma/delta T cell lymphomas are derived from different Vdelta subsets of gamma/delta T lymphocytes.

Authors:  G K Przybylski; H Wu; W R Macon; J Finan; D G Leonard; R E Felgar; J A DiGiuseppe; P C Nowell; S H Swerdlow; M E Kadin; M A Wasik; K E Salhany
Journal:  J Mol Diagn       Date:  2000-02       Impact factor: 5.568

Review 3.  Treatment of T-cell non-Hodgkin's lymphoma.

Authors:  Andrew M Evens; Ronald B Gartenhaus
Journal:  Curr Treat Options Oncol       Date:  2004-08

4.  Hepatosplenic gammadelta T-cell lymphoma with ring chromosome 7, an isochromosome 7q equivalent clonal chromosomal aberration.

Authors:  Julia Tamaska; Emma Adam; Andras Kozma; Laszlo Gopcsa; Hajnalka Andrikovics; Attila Tordai; Gabriella Halm; Laszlo Bereczki; Eniko Bagdi; Laszlo Krenacs
Journal:  Virchows Arch       Date:  2006-08-29       Impact factor: 4.064

Review 5.  [Malignant lymphomas of the liver: new diagnostic algorithms].

Authors:  T Longerich; P Schirmacher; H P Dienes; H Stein; C Loddenkemper
Journal:  Pathologe       Date:  2006-07       Impact factor: 1.011

6.  Nonhepatosplenic γδ T-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation.

Authors:  Adriana Garcia-Herrera; Joo Y Song; Shih-Sung Chuang; Neus Villamor; Luis Colomo; Stefania Pittaluga; Tomas Alvaro; Maria Rozman; Jazmin de Anda Gonzalez; Ana Maria Arrunategui; Eva Fernandez; Elena Gonzalvo; Teresa Estrach; Dolors Colomer; Mark Raffeld; Philippe Gaulard; Elias Campo; Elaine S Jaffe; Antonio Martinez
Journal:  Am J Surg Pathol       Date:  2011-08       Impact factor: 6.394

Review 7.  Is there truly a risk of lymphoma from biologic therapies?

Authors:  Erica Dommasch; Joel M Gelfand
Journal:  Dermatol Ther       Date:  2009 Sep-Oct       Impact factor: 2.851

8.  CD4(-)/CD8(-) variant of T-cell large granular lymphocytic leukemia or hepatosplenic T-cell lymphoma: a clinicopathologic dilemma.

Authors:  Ohad Benjamini; Preetesh Jain; Sergej N Konoplev; Cheng Cameron Yin; Lynne Abruzzo; Andrew C Wotherspoon; Claire Dearden; Elizabeth J Shpall; Zeev Estrov; Michael J Keating
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-06-22

9.  Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment.

Authors:  G S Falchook; F Vega; N H Dang; F Samaniego; M A Rodriguez; R E Champlin; C Hosing; S Verstovsek; B Pro
Journal:  Ann Oncol       Date:  2009-02-23       Impact factor: 32.976

Review 10.  Gamma-delta T-cell lymphomas.

Authors:  Claudio Tripodo; Emilio Iannitto; Ada Maria Florena; Carlo Ennio Pucillo; Pier Paolo Piccaluga; Vito Franco; Stefano Aldo Pileri
Journal:  Nat Rev Clin Oncol       Date:  2009-11-10       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.